Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Denovo Biopharma In-licenses Second Drug Candidate from Lilly

publication date: Mar 3, 2015
Denovo Biopharma, a San Diego company with a lab in Hangzhou, obtained global rights to a late-stage neuroscience drug from Eli Lilly. The drug is Pomaglumetad Methionil (mGlu2/3 receptor agonist), a proposed treatment for schizophrenia. Although the drug failed to meet its endpoints in a Phase III trial, subsets of the enrolled patients had very successful outcomes. Denovo will use its platform to identify genetic biomarkers of these subsets and develop a companion diagnostic, both for the trial and eventual patient use. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital